newsfilter
← Latest News
Business Wire·

Kardigan Reports Second Quarter 2026 Financial Results and Recent Business Updates

  • Kardigan reported second quarter 2026 financial results & provided business updates as of June 30, 2026
  • Danicamtiv Phase 3 KINSHIP-DCM Cohort 1 enrollment is complete, with Phase 3 enrollment now underway & Phase 2b topline data expected in the first half of 2027
  • Ataciguat Phase 2b KATALYST-AV trial is ongoing, with interim topline data expected in the first half of 2027
  • Tonlamarsen Phase 2b KARDINAL-ASH trial randomized its first patient in the second quarter, with Phase 2 topline data expected in the first half of 2027
  • Preclinical & clinical data for danicamtiv regarding right ventricular function will be presented at ESC 2026 on August 30
  • Extended follow-up data for tonlamarsen regarding uncontrolled hypertension will be presented at ESC 2026 on August 30
  • Kardigan closed its IPO in June 2026 with $460 million in aggregate gross proceeds
  • Cash, cash equivalents, & investments totaled $660.7 million as of June 30, 2026, providing a runway through multiple data readouts & Phase 3 trial initiations
  • Research & development expenses were $56.4 million for the quarter, driven by clinical trial costs & increased headcount
  • General & administrative expenses were $18.9 million for the quarter, a decrease from $21.3 million in the prior year period due to a one-time integration bonus in the prior year
  • Net loss for the quarter ended June 30, 2026, was $116.2 million, an increase from $57.4 million in the comparable prior-year period primarily due to higher R&D expenses
  • Kardigan is advancing three late-stage programs supported by its Prolaio platform to address cardiovascular diseases with no approved treatments